What is Aardvark Therapeutics, Inc. Common Stock (AARD) stock price today?

Aardvark Therapeutics, Inc. Common Stock (AARD) currently trades at $5.21 per share. The stock has a market capitalization of $113.66M and a P/E ratio of —x.

Is AARD stock a buy, sell, or hold in 2026?

Based on WallStSmart's proprietary analysis, Aardvark Therapeutics, Inc. Common Stock has a Smart Value Score of 28/100 (Grade F), resulting in a "Strong Sell" investment rating. The Piotroski F-Score is 4/9 and Altman Z-Score is —.

Is Aardvark Therapeutics, Inc. Common Stock financially healthy?

Aardvark Therapeutics, Inc. Common Stock's Piotroski F-Score is 4/9 (moderate financial health). The Altman Z-Score of — places it in the —.

AARD

Aardvark Therapeutics, Inc. Common Stock

NASDAQ: AARD · HEALTHCARE · BIOTECHNOLOGY

$5.21

-6.80% today

Updated 2026-04-29

Market cap

$113.66M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.93

Dividend yield

—

52W range

$3 – $18

Volume

0.3M

Market cap

$113.66M

P/E ratio

—

P/S ratio

—

EPS (TTM)

$-2.93

Dividend yield

—

52W range

$3 – $18

Volume

0.3M

WallStSmart proprietary scores

out of 100

Grade: F

Strong Sell

Investment rating

4.3

Growth

7.8

Quality

B+

3.0

Profitability

5.0

Valuation

C+

4/9

Piotroski F-Score

Moderate

—

Altman Z-Score

—

Industry rank

—

View all highly rated stocks (75+) →201 stocks currently score above 75

Price targets

Analyst target

$16.90

+224.38%

12-Month target

—

Intrinsic (DCF)

—

Margin of safety

—

0 Strong Buy8 Buy4 Hold0 Sell0 Strong Sell

Price chart

X-Ray snapshot

Strengths

+ Debt/equity 0.00x — low leverage

Risks

- Thin margins at 0.00%

- Negative free cash flow $-14.42M

Key financials

Revenue Net Income Free Cash Flow

Metric	2022	2023	2024	2025	TTM
Revenue	$0.00	$0.00	$0.00	$0.00	$0.00
Net income	$-13.56M	$-7.21M	$-20.59M	$-57.59M	$-17.60M
EPS	—	—	—	—	$-2.93
Free cash flow	$-10.54M	$-5.82M	$-18.20M	$-54.27M	$-14.42M
Profit margin	—	—	—	—	—

Peer comparison

Company	Mkt Cap	Score	Growth	Profit	Value	Quality	MoS	Rating
AARD	$113.66M	28	4.3	3.0	5.0	7.8	—	Avoid
LLY	$760.43B	78	10.0	10.0	5.0	6.5	—	Strong Buy
JNJ	$547.28B	59	4.7	9.0	3.3	6.0	-43.54%	Buy
ABBV	$360.63B	63	4.0	8.0	4.7	5.0	-29.31%	Buy
UNH	$322.34B	54	5.3	5.5	7.3	4.8	+42.06%	Buy
AZN	$294.17B	64	6.7	8.0	5.3	5.0	+4.07%	Buy

Smart narrative

Aardvark Therapeutics, Inc. Common Stock trades at $5.21. Our Smart Value Score of 28/100 indicates the stock is weak. The company scores 4/9 on the Piotroski F-Score.

Frequently asked questions

What is Aardvark Therapeutics, Inc. Common Stock's stock price?

Aardvark Therapeutics, Inc. Common Stock (AARD) trades at $5.21.

Is Aardvark Therapeutics, Inc. Common Stock overvalued?

Smart Value Score 28/100 (Grade F, Strong Sell).

What is the price target of Aardvark Therapeutics, Inc. Common Stock (AARD)?

The analyst target price is $16.90, representing +224.4% upside from the current price of $5.21.

Piotroski F-Score?

4/9 — moderate financial health.

Company info

SectorHEALTHCARE

IndustryBIOTECHNOLOGY

CountryUSA

ExchangeNASDAQ

CurrencyUSD

aardvarktherapeutics.com

Quick metrics

P/S ratio—

ROE-64.40%

Beta—

50D MA$6.03

200D MA$10.66

Shares out0.02B

Float0.01B

Short ratio—

Avg volume0.3M

Performance

1 week—

1 month—

3 months—

YTD—

1 year—

3 years—

5 years—

Compare

AARD vs LLY →AARD vs JNJ →AARD vs ABBV →Stock screener →